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The  recently-deﬁned  four  molecular  subgroups  of  medulloblastoma  have  required  updating  of  our  under-
standing of in  vitro  models  to include  molecular  classiﬁcation  and  risk  stratiﬁcation  features  from  clinical
practice.  This  review  seeks  to build  a more  comprehensive  picture  of  the  in  vitro  systems  available  for
modelling  medulloblastoma.
The  subtype  classiﬁcation  and  molecular  characterisation  for over  40 medulloblastoma  cell-lines  has
been compiled,  making  it possible  to identify  the  strengths  and  weaknesses  in  current  model  systems.
Less  than  half  (18/44)  of established  medulloblastoma  cell-lines  have  been  subgrouped.  The  majority  of
the  subgrouped  cell-lines  (11/18)  are Group  3 with  MYC-ampliﬁcation.  SHH  cell-lines  are  the next  most
common  (4/18),  half  of which  exhibit  TP53 mutation.  WNT  and  Group  4 subgroups,  accounting  for  50%
of  patients,  remain  underrepresented  with  1  and  2 cell-lines  respectively.ormal brain co-culture In vitro  modelling  relies  not  only  on incorporating  appropriate  tumour  cells,  but also  on using  sys-
tems  with  the  relevant  tissue  architecture  and  phenotype  as  well  as  normal  tissues.  Novel  ways  of
improving  the  clinical  relevance  of  in  vitro models  are  reviewed,  focusing  on  3D  cell culture,  extracellular
matrix,  co-cultures  with  normal  cells  and  organotypic  slices.  This paper  champions  the  establishment  of
a collaborative  online-database  and  linked  cell-bank  to catalyse  preclinical  medulloblastoma  research.
©  2016  The  Author(s).  Published  by Elsevier  B.V.  This  is an  open  access  article under  the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
ontents
1. Introduction  . .  .  . . .  . .  .  . . .  . . . .  . . . .  . . . .  . . .  .  . . .  .  . . .  .  . . . .  . . .  . . . .  . . .  . . . . .  . .  . . . . .  . .  .  . . . .  . .  .  . . . . . .  .  . . . . . .  .  . . . . . . .  . . . .  .  . .  . .  .  .  .  . . .  . .  .  .  . . .  . .  . .  .  .  .  .  .  .  . .  . . . . .  . . . .  .  .  .  .  .  11
2.  The  current  classiﬁcation  of  medulloblastoma  .  .  . . . . . . . . . . . .  . . . . . .  .  . . . . . . . . . . . . .  . .  . . . . . .  .  .  .  . .  . . .  . . . . . . .  .  . . . .  . . .  . .  .  .  . . . . . . . . . . . .  . .  .  .  .  .  . . . . . .  . .  . . . .  .  .  .  .  .  . 12
2.1.  Histology  .  . . .  . . .  .  .  . .  .  . . .  .  . . . .  . . . . . .  . . .  .  . . .  .  .  . . .  . . . .  . . . . . .  . . . .  . . . . . . . .  .  . .  .  .  . . . . .  . . . . .  . . .  . . . .  .  . . . . . . .  . . .  . . . . . . .  .  . . .  . . . .  .  . .  . . . . .  .  . . . . .  . .  .  .  .  .  . . . .  . . . . 12
2.2. Molecular  subgroups  of  medulloblastoma.  .  . . .  .  . .  .  .  . . . . . . .  . . .  . . . . . . . . .  . . . .  . . .  . . . . . .  .  . . .  .  . . .  .  . . .  . . . . . . . . . . .  . . . . .  . . .  .  . . .  .  .  . . .  . . . . . .  .  . . .  .  . .  . . .  .  .  .  .12
2.2.1. WNT  .  . . .  .  . . .  . . . .  . . . .  . . .  .  . . .  .  . . .  . . .  .  . . .  . . . .  .  . . .  .  . . .  . . .  .  . . .  .  .  . . . . . . .  . . . . .  . . .  . . . . .  . . .  . . .  . . .  .  . . .  .  . . . .  . . . . . . . .  . . . . .  .  . . .  . . . . . .  .  . . .  .  .  .  . . . . . . .  . 12
2.2.2.  SHH  . .  . . .  .  . . .  .  . .  .  .  . .  . . . . . . . .  . . .  .  . . .  .  . . .  .  .  .  .  .  .  . .  . . .  . . . .  .  . . .  . .  . . . . .  . . .  .  . . . . .  . . . . . . .  .  . . . .  . . .  . . . . . .  .  . . . . . .  .  . . . . . . .  . .  .  . .  .  . . . . . .  .  .  .  .  . .  .  . .  . . . . .  12
2.2.3.  Group  3 . .  . . . . .  . .  . . . .  . . .  . . . .  .  . . . .  . . . . . . . . . . . . . .  . . . .  .  . . . . . .  . . . . . . .  . .  . . . . . .  .  .  . . .  . .  .  . . . . . .  .  .  . . . . .  .  . . . .  . . .  . . . .  .  . . . .  .  . .  .  .  .  .  . . . .  . . . .  .  .  . .  .  .  .  .  .  . 12
2.2.4.  Group  4 . .  . . . . .  . .  . . . .  . . .  . . . .  .  . . . .  . . . . . . . . . . . . . .  . . . .  .  . . . . . .  . . . . . . .  . .  . . . . . .  .  .  . . .  . .  .  . . . . . .  .  .  . . . . .  .  . . . .  . . .  . . . .  .  . . . .  .  . .  .  .  .  .  . . . .  . . . .  .  .  . .  .  .  .  .  .  . 12
2.3.  Immunohistochemistry  and  other  techniques  for  subgroup  classiﬁcation  . . .  .  . . .  . . . . .  . . .  . . . . . . .  . . . . .  . .  .  . . . . .  .  . . . . .  . .  .  .  .  .  .  .  .  . . . . .  .  . . . . . . .  .  .  .  .  . 12
3.  In  vitro  models  of medulloblastoma  tumours  . . . . . . . . . . . . . .  . . .  . . . . . . .  .  .  . . . .  .  .  .  . . .  . . .  . . . .  . .  .  . . . . . .  . . . . .  . . .  . . . .  . . .  . . .  . . . . . . .  .  . . . .  .  .  .  .  .  . . . . . . . . . .  .  . .  . . .  . .  . 12
3.1.  Primary  medulloblastoma  cultures  . . . . . . .  . . . .  . . .  .  .  . .  .  .  . .  . . . .  .  . . .  .  . . . . .  .  .  . .  . . .  . . . . .  . . .  . . . .  .  . . . . . .  . . . . . . .  .  .  . . . . .  .  . . . . . .  .  . . .  .  .  .  . . . . . . . . . .  . .  .  .  .  .  . . .  12
3.2.  Established  cell-lines  . . . . . .  . . . . . . .  . . .  .  .  . . .  . . . . . . .  . . . .  . . .  .  . . . . . .  .  . . . .  . .  .  .  . . . . .  .  .  . . .  . .  .  . . . . . . .  . . . . .  . . .  . .  . . . . .  . . .  .  . . .  .  .  . .  . . .  .  .  .  . .  . . . . . . . . . .  . .  .  .  . . .  .  .  13
3.2.1.  Linking  the  data  to patients  – proportion  of  patient  tumours  covered  . . .  . . . . . . .  .  . . . .  . . .  . . . .  .  . . .  . . .  . . .  .  .  .  .  .  . . . . . . . . . . .  .  . .  .  . .  . . . .  . . .  . . 16
3.2.2.  GEMM  cell-lines  .  . . .  .  . . . .  . . .  .  . . .  .  .  . .  . . .  .  .  . .  . .  . .  . . . .  .  . . . .  .  . . . . . .  . . . . . . .  .  . . . .  .  . . .  .  . . .  . . .  . . . . . .  .  .  . . .  .  . . .  . . .  .  .  .  .  . . .  .  .  . . . .  . . . . . .  . .  .  .  .  .  . . .  .  . . 17
4.  In  vitro  models  of the normal  brain  .  . . .  .  . . .  . . . . .  . . .  . . .  .  . . .  . . .  .  . . . . . . .  . . . .  . . .  .  . . . . . . . .  .  . . .  . . . . . . .  . . .  . . .  . . . . .  . . . . . . .  .  . .  . . . .  .  . . . .  .  . . . .  .  . . .  .  .  .  . . .  . . . . . .  .  . . .  .  17
4.1. Reasons  to include  the  normal  brain . . .  . . . .  . . . .  .  . . .  .  . . . . . .  .  . .  . . . . .  . 
4.2. Rodent  neural  stem  cells  . . .  .  . . .  . . . .  .  . .  .  .  . . .  . . . . . . .  . . . .  . . .  .  . . . . . .  .  . . 
4.3.  Transformed  human  cells  . . . .  . . .  .  . . .  .  . . . . . . . . . .  . . . .  . . .  .  .  . . . . .  .  . . . .  .  .
∗ Corresponding author at: Cancer Biology, Division of Cancer and Stem Cells, Queen’s 
E-mail  addresses: delyan.ivanov@nottingham.ac.uk (D.P. Ivanov), beth.coyle@nottingh
nna.grabowska@nottingham.ac.uk (A.M. Grabowska).
ttp://dx.doi.org/10.1016/j.jbiotec.2016.07.028
168-1656/© 2016 The Author(s). Published by Elsevier B.V. This is an open access article. . . . . . . . .  . . .  . .  .  . . . . . .  .  .  . .  . . . . .  . . .  . . . . .  . . . . . .  .  . . . . . .  .  . . .  . . . .  . .  .  .  .  .  . . .  .  . . . . .  . . .17
. .  .  .  .  .  . . . .  . . .  . . .  . .  . . .  . . . . .  . .  . . . . . . .  . . . . . . . .  .  . . . . . . . .  . . . . . . .  .  . . .  .  .  .  . . .  . .  . . . .  . . 17
 . .  .  . . .  . .  . . . . . . .  .  .  . .  . . . . .  . . .  . .  .  . . .  .  . . .  .  .  . . . . . . .  .  . . .  .  . . . .  .  . .  .  .  .  .  . . . .  . . . . .  .  . . .  . 17
Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.
am.ac.uk (B. Coyle), david.walker@nottingham.ac.uk (D.A. Walker),
 under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
D.P. Ivanov et al. / Journal of Biotechnology 236 (2016) 10–25 11
4.4.  Human  neural  stem  cells  .  . . . .  . . . .  . . .  .  . . .  .  . . .  .  . . .  .  . . . . .  .  .  . . . . .  .  . . . .  . . . . . . .  .  . . . . . .  . . . . .  . . .  . . . .  . . .  . .  . . .  . .  . . . . . . .  .  .  . .  .  . . . .  .  . .  .  .  .  .  . . . . . . . . .  . . . .  . .  . . . .  17
5.  Three-dimensional  models  . .  .  .  . .  . . . .  . . .  . . . .  .  . . .  .  . . .  .  . . . . . . .  . . . . . .  . . . .  . . . . . . .  .  . .  . . .  . . . . . . .  . . . . . . .  .  . . .  .  . . . .  . .  . . . . .  .  . .  . . . . .  .  .  .  . . .  . . . . . .  . . . . . . .  . . . .  . .  .  .  .  . .  . 18
5.1.  Why  3D? .  .  . . . . .  .  . . .  . . . .  . . .  .  .  . .  . . . .  . . . .  . . . .  . . .  .  . . .  . . . .  . . . . . .  . . . . .  . .  .  . . . . . .  .  . . . . . .  . . . . . . .  .  . . . .  . . .  . . . . .  . . .  . .  . . . . . . . .  .  . . .  . . . . . . . . . . . .  .  .  .  .  . .  .  . .  . . . .  .  . . 18
5.2.  Multicellular  3D  tumour  spheroids  . . .  . . .  . . . .  .  . . .  . . . .  . . .  .  . . .  . .  . . . . .  . . . .  . . . .  . . .  . . .  . .  .  . . . .  . . .  . .  . . .  . . . . .  . . . . .  .  . . . . .  . . .  .  .  .  . . . . . . . . .  . .  .  .  . .  .  .  . .  .  . .  . .  .  . 18
5.3.  Three-dimensional  normal  brain  component  . . . . . . .  . . . . . . .  . . . . . . . . . .  . . .  . .  . . . . . . .  . . . . . . .  . . . . .  . .  .  . .  . . . . . . . .  . . . .  . .  .  .  . . . . .  . .  .  .  .  .  . . . . . . .  . . .  . .  .  . .  . .  .  18
5.4.  Spheroid  co-cultures  . . .  . . .  .  . . .  .  . . .  . . .  .  . . .  . . . .  .  . . .  .  . . .  . . . .  . . . .  .  .  . . .  . .  .  . . . . . .  .  . . . . .  . . .  . . . . .  . . . .  . . .  . . .  . . .  . . . . .  . . . . . . .  .  . . . .  .  . . . .  . . . . . .  . . .  .  .  .  . . . . . . . .  18
5.5.  ECM  . .  . . .  .  . . .  .  . . . .  . . .  . . . .  . . .  . . .  .  . . .  .  . . . . . . . . . . . . . . . . . .  . . . . . . .  . . . . . . .  .  . .  . . . . .  . .  . . .  . . .  . . . . . .  .  . . . . .  .  . .  . . .  .  . . . .  . . .  . . . .  .  . . . .  .  .  . . . . . . . . .  .  . .  .  . .  .  . . .  . . . . . .  18
5.6.  Organotypic  ex  vivo models  with  cerebellar  slices  . . . . . .  . . . . .  . .  . . . . .  . .  .  . . . . . .  .  . . . . . .  . . . . . . .  .  .  .  . .  . . .  .  . . . .  . .  .  . .  .  .  . . . . .  . .  .  .  .  .  .  . . . .  .  .  . . .  .  . . .  .  .  .  .  . .  . 19
6. Data  register/Cell-line  database  . .  .  .  . .  . . . .  . . .  . . . .  . . . .  .  . . .  . . . .  . . .  . .  .  . . . .  . . . . . . .  . .  . . .  .  . . .  . . . .  . .  . . . . . . . . .  . . .  . .  .  . . . . . . .  . . . .  . .  . . . . . . .  .  . . . . . .  .  . .  .  . .  . . .  .  . . .  . . .  .  19
7.  Conclusions  and  future  directions  . . .  . . . . . . .  . . . .  . . . .  .  . . .  . . . .  . . .  . . .  .  . . . . . . .  .  . . . . . .  . . .  . . . . .  . . .  . .  .  . . .  .  . . .  . .  . . .  . . . .  .  . . .  . . . . .  . . .  . .  . . . . .  . .  .  .  .  .  . . . .  .  . . . . .  . . .  . . . 19
Acknowledgements .  . .  .  . . .  .  . .  .  . . .  . . . . . . .  .  . . . .  . . . .  . . .  . . . .  .  . . . . . . .  . . . .  . . .  .  .  .  . . . . . . .  . . . . . .  . . . . . . .  .  .  . . .  . . . . .  . . .  . .  . . . .  . . . .  . . .  .  . . .  . . . . . .  . . .  . .  .  . .  .  . . . . . .  .  . . .  . .  .20
Appendix  A.  Supplementary  data  . . . . . .  . . .  .  . . .  .  .  . . . . . .  .  . . . . . .  .  . . . .  .  . .  . . . . . . .  . . .  .  . . . . . . .  . .  . . . .  .  . . .  . . . .  .  .  . . . . . . . . . . . . .  .  . . . . . . . . .  .  .  .  . . .  .  . .  . . . .  .  . . .  . .  . .  .  20













































tReferences  .  .  . . . . . . .  .  . . .  .  . . .  . . . .  . . . .  .  . . .  . . . . . . .  . .  . .  .  . .  .  .  . .  . . . . .  . . . . . . .  .
. Introduction
After accidents, childhood cancers are the most common cause
f death in children older than 1 year in the developed world (Ward
t al., 2014; WHO, 2015). On the global scale around 300,000 chil-
ren and adolescents are diagnosed with cancer per year (Ferlay
t al., 2013). Because paediatric malignancies occur early in life,
hey result in a tremendous loss of quality-adjusted-life-years both
rom death and from poor quality of life, due to the disabling conse-
uences of treatment in surviving patients. That is why  this group
f childhood diseases has a profound effect on children themselves,
heir family, the healthcare system and society as a whole.
While leukaemia is the commonest cancer in childhood
ccounting for 30% of paediatric malignancies, brain and central
ervous system (CNS) tumours are the most frequent in the solid
umour group making up 20% of childhood cancers (Ward et al.,
014). The most common paediatric malignant brain tumour is
edulloblastoma, which is an embryonal tumour of the cere-
ellum. Medulloblastoma incidence rates peak at 6 children per
illion under 9 years of age and tail off to under 2 cases per mil-
ion in the 15–19 age group (Ostrom et al., 2015). Overall, there
re around 400 cases of medulloblastoma diagnosed in the US, 80
n the UK and an estimated 5000–8000 cases per year worldwide
Ferlay et al., 2013; Ostrom et al., 2015).
Current treatment for medulloblastoma combines surgery,
adiotherapy and chemotherapy. This multimodal approach has
ransformed medulloblastoma from a virtually incurable disease
n the beginning of the 20th century, to a manageable condition
here 70% of children survive over 5 years and 58% for more than
5 years (Ward et al., 2014).
The increase in survival comes at the expense of serious and
ften long-lasting side effects. Medulloblastoma surgery carries a
5% risk of cerebellar mutism syndrome (Robertson et al., 2006),
onsisting of temporary total loss of speech, reduced co-ordination
nd balance. Although children eventually recover, they are left
ith lifelong defects in speed of processing, affecting all motor and
ognitive functions. After surgery, adjuvant craniospinal radiother-
py is used to treat the whole brain and spine in medulloblastoma
n order to prevent medulloblastoma dissemination in the cere-
rospinal ﬂuid (CSF). While craniospinal radiotherapy undoubtedly
rolongs survival, it does so at the expense of 2–4 point IQ decrease
er year (Mulhern et al., 2005) due to radiation-induced brain
njury. Radiation has greater consequences for younger patients
nd is therefore contraindicated in children less than 3 years of age.
ther toxicities from radiotherapy include impaired spinal growth
nd endocrine dysfunction. Together these side effects lead to
educed independence for patients and premature ageing (Boman
t al., 2013). Despite hopes that proton therapy would have a move
avourable side-effects proﬁle by offering highly conformal dosime-
ry whilst sparing organs outside the brain, this treatment still .  . . . .  . . . . . .  . . . .  .  .  . .  .  . . . . . . .  . . . . . . .  .  . . . .  . . .  .  . . .  .  .  . . .  . . .  .  . . .  . . . .  . . .  . . .  . .  . .  . .  .  .  20
requires whole brain and spine dosing with predictably similar CNS
consequences (Yock et al., 2016). Therefore, the only way to reduce
the incidence and severity of radiotherapy-induced side effects on
the brain is to lower the radiation dose in those patients at reduced
risk of tumour recurrence and dissemination and offer alternative
adjuvant treatments. Chemotherapy, as the second adjuvant can-
cer treatment, offers this opportunity. Optimising techniques for
the selection of chemotherapeutic agents targeted at the molecu-
lar subgroups of medulloblastoma and their application is the focus
of this review.
Medulloblastomas are generally considered sensitive to conven-
tional chemotherapy agents. Tumours exhibit objective responses,
and patients on chemotherapy have increased event-free survival
(Taylor et al., 2003). Disappointingly, a recent Cochrane review
could not ﬁnd evidence of chemotherapy improving overall sur-
vival in randomized clinical trials comparing regimens with and
without chemotherapy (Michiels et al., 2015). Nevertheless, indi-
vidual chemotherapy studies have reported 5-year overall survival
rates greater than 80% in low-risk patients, without metastatic dis-
ease at diagnosis and complete resections (Packer et al., 1999).
Similarly in a subset of desmoplastic medulloblastoma in infants,
chemotherapy-only regimens have been reported to result in 5-
year overall survival rates of 80% in patients younger than 3 years,
in whom irradiation is contraindicated (von Bueren et al., 2011).
The uncertainties of the contribution of chemotherapy to overall
survival come from the empirical introduction of chemotherapy
protocols to clinical practice and the lack of rational methods
to predict individual patient response. Historically, chemother-
apy clinical trials in medulloblastoma have been initiated based
on anecdotal evidence and manageable side-effect proﬁles, rather
than tumour target expression and drug-target engagement evi-
dence.
The current challenge in chemotherapy is to identify which of
the conventional chemotherapy agents and which new targeted
drugs might be expected to work best in each of the new molecu-
lar subtypes of medulloblastoma. The constraints of low numbers of
eligible patients and the signiﬁcant costs and time involved for clin-
ical trials necessitates a systematic preclinical screening strategy in
order to select the best agents for the clinic. A rational approach
to improving medulloblastoma therapy would rely on consecu-
tive in vitro studies demonstrating intrinsic tumour sensitivity
and lack of toxicity, followed by in vivo experiments documenting
achievable tumour exposure levels and response to therapy. While
preclinical data may  not be able to predict patient response, they
can increase the conﬁdence in novel drugs through elucidation of
mechanisms of action and resistance (Cook et al., 2014). Preclinical
data can also be used to calculate theoretical exposures for tumour
response and subsequently prioritise treatment strategies with the
highest chance of success in the clinic. In this respect it is vital to
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n order to identify patients who are most likely to beneﬁt from a
ertain treatment.
The aim of this review is to systematise the available evidence
n in vitro models of medulloblastoma and allow researchers to
ake informed choices on the usefulness of certain cell-lines, cul-
ure conditions and experimental setups. As medulloblastoma is
o longer viewed as one disease, in vitro models that are repre-
entative of patient molecular subtypes and can be used to stratify
atients for subgroup-speciﬁc therapies are essential.
. The current classiﬁcation of medulloblastoma
.1. Histology
According to the old 2007 WHO  classiﬁcation, medulloblas-
oma was divided into four groups based on their histopathological
eatures: classical, desmoplastic, medulloblastoma with extensive
odularity (MBEN) and large/cell anaplastic (Louis et al., 2007).
hile histology has been historically important in identifying
igh-risk patients (large-cell anaplastic) or those with favourable
rognosis (infants with desmoplastic or MBEN morphology), it fails
o stratify the majority of patients with classical histology.
.2. Molecular subgroups of medulloblastoma
Extensive genomic studies have shown that medulloblastoma
s not a single entity but is comprised of four distinct molecular
roups (Taylor et al., 2012). The molecular subgroups have dif-
erent genetic, epigenetic and phenotypic proﬁles and can predict
atient risk and outcome. They are included in the latest 2016 WHO
rain tumour classiﬁcation as an additional “layer” alongside histol-
gy. Recent publications have revealed a complex risk-stratiﬁcation
ubdivision within the molecular subgroups, identifying a number
f smaller groups within the big four with better or worse prognosis
Ramaswamy et al., 2016; Shih et al., 2014).
.2.1. WNT
Around 10% of medulloblastoma tumours exhibit aberrant WNT
ignalling with the majority of mutations in exon 3 of CTNNB1,
uclear expression of -catenin and loss of chromosome 6. This
roup carries the best prognosis with over 95% of patients surviv-
ng over 5 years (Ellison et al., 2005). Recent studies have reported
hat patients with WNT-driven medulloblastoma have leaky blood
essels lacking the markers associated with an intact blood-brain
arrier(Phoenix et al., 2016). These ﬁndings, suggesting potential
or better drug access, may  explain the increased chemosensitivity
f WNT  tumours and the favourable prognosis for patients.
.2.2. SHH
The sonic hedgehog (SHH) pathway is perturbed in 30% of
edulloblastoma tumours. This group combines patients with
utations in any of the factors in the SHH signalling pathway
PTCH1, SMO, SUFU, GLI1, and GLI2), leading to heterogeneity in
isease presentation, response to therapy and outcome. While 5-
ear survival in the SHH group as a whole is around 64%, patients
ith either metastatic disease, MYCN,  GLI2 ampliﬁcations or chro-
osome 14q loss (Shih et al., 2014) and especially those with
utations in TP53 (Ramaswamy et al., 2016) have a very poor
rognosis (<50% survival).
.2.3. Group 3
Group 3 tumours comprise around 20% of medulloblastomaases often present with metastatic disease at diagnosis and lead to
elapse. This group carries the worst prognosis with less than 50%
-year survival. While Group 3 has often been labelled as the MYC
ubgroup (Hatten and Roussel, 2011), MYC  expression (mRNA orchnology 236 (2016) 10–25
protein) is not prognostic and cannot inform subgroup classiﬁca-
tion. Since MYC  is a downstream target of WNT  signalling (Roussel
and Robinson, 2013), MYC  expression is also seen in the favourable
WNT  group. Superior prognostic high-risk factors within this group
are MYC ampliﬁcations, seen in 17% of Group 3 tumours (3–4%
of medulloblastoma patients as a whole) or isochromosome 17q
(iso17q) which separately carry a poor prognosis (Shih et al., 2014).
2.2.4. Group 4
Group 4 tumours comprise the largest group (40% of patients).
They occur predominantly in boys, carry an intermediate progno-
sis (70%, 5-year survival) and often exhibit iso17q. Although iso17q
is also seen in Group 3 tumours (26%) it is much more common
(66%) in Group 4 tumours (Northcott et al., 2011). While Group 3
and 4 tumours share other chromosomal abnormalities (e.g. gain
of chromosome 18 and loss of 11p) and have similar gene expres-
sion features (e.g. OTX2, FOXG1B) they are molecularly distinct
(Northcott et al., 2011). Prognostic factors within the group are
chr11 loss or chr17 gain which were reported to be associated with
favourable prognosis (Shih et al., 2014). A recent study has identi-
ﬁed the LIM homeobox transcription factor 1 (LMX1A) as a major
regulatory factor in Group 4 medulloblastoma, implicating progen-
itors from the upper rhombic lip as the cells-of-origin for Group 4
tumours (Lin et al., 2016). Nevertheless, Group 4 continues to be
the largest and least understood subgroup of medulloblastoma.
2.3. Immunohistochemistry and other techniques for subgroup
classiﬁcation
Regarding immunohistochemistry, Northcott et al., 2011
advocated an affordable four-antibody approach to classify medul-
loblastoma tumours to the four molecular subgroups. However,
subsequent studies have only been able to classify tumours into
WNT, SHH and a mixed Group3/4 using this approach (Bien-Willner
et al., 2012; Kaur et al., 2015; Min  et al., 2013). This failure has been
attributed to the poor ability of the NPR3 and KCNA antibodies to
differentiate between Groups 3 and 4. That is why the current gold
standard for subgroup proﬁling remains a choice between whole
genome transcriptional array proﬁling (Taylor et al., 2012), employ-
ing a Nanostring panel of 22 genes (Northcott et al., 2012b) or
methylation proﬁling (Schwalbe et al., 2013). A subgroup classi-
ﬁcation algorithm combining complimentary techniques has been
suggested by (Gottardo et al., 2014). Additionally, a panel of ﬂuores-
cence in situ hybridization (FISH) tests (GLI2, MYC, 14q, 17p, 17q,
and 11q) has been promoted as a “pathology-friendly” technique
for risk stratiﬁcation (Shih et al., 2014).
3. In vitro models of medulloblastoma tumours
In vitro laboratory experiments on primary tissue and estab-
lished cell-lines are routinely employed to test biological
hypotheses and prioritise treatment strategies in cancer. While tak-
ing a tumour out of the body and placing it in an artiﬁcial mix  of
nutrients is a signiﬁcant departure from the in vivo situation, the
advantage of in vitro methods stems from the possibility of employ-
ing human patient-derived tissue, expanding the cells and using
them in a broad range of experiments that are both inexpensive
and yield rapid results.
3.1. Primary medulloblastoma cultures
The initial in vitro culture of cells and tissues harvested from
patients or animals is deemed primary culture. While, primary
cultures bear the highest resemblance to the in vivo state, they
are often a heterogeneous mix  of different cells. This makes them
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nd ﬁndings which are difﬁcult to reproduce by others. After the
rst passage, primary cultures are classed as early-passage cul-
ures, where the cells are increasingly put under selective pressure
n the cell culture media. Eventually, after a number of passages
he cells either stop dividing (ﬁnite cell-lines) or they continue to
ivide forming continuous cell-lines. A key advantage of primary
nd early-passage cultures over long-established cell-lines is that
hey can be readily compared to the original tissue and the degree
f similarity can be quantiﬁed, whilst long-established cell-lines
ay  have adapted to in vitro growth conditions and the original
atient tissue is rarely available.
Alternatively patient-derived tumour cells can be cultured and
assaged in immunocompromised mice, preferably orthotopically,
n the natural anatomical location (Shu et al., 2008). The theoreti-
al advantages of this approach are that cells are not subjected to
n vitro selection pressure of artiﬁcial media and that tumour cells
re cultured in a more physiologically-relevant microenvironment.
lthough the introduction of tumour cells in mouse cerebellum
as been historically challenging, Shu et al., 2008 have shown
hat tumour tissue from a single patient can be expanded into
00–2000 mice with 50% success rate and serially-passaged for
p to 5 passages. This approach not only allows for expanding
he tissue from one patient into multiple in vivo models, but the
atient-derived tumours can later be cultured in vitro and subjected
o high-throughput screens (Onion et al., 2016). Nevertheless, sys-
ematic genotyping and gene expression studies (Shu et al., 2008;
hao et al., 2012) have indicated differences between patients and
rimary orthotopic xenograft cultures in 69 genes, involved in RAN,
TAT and TP53 signalling (Fig. 2 and Supplementary Fig. S2a in
Zhao et al., 2012)). Furthermore, subsequent passaging in vivo was
hown in the same studies to introduce genetic drift (up to 30 gene
ifferences between passage 1 and 3) and loss of heterozygosity.
he underlying reasons for these differences could be the mechan-
cal and enzymatic dissociation procedures, the replacement of
uman with mouse stroma or selection bias for aggressive sub-
lones from the patient’s tumours. Therefore, despite differences
etween the two modalities, both in vitro and in vivo passaging
ntroduce selection pressure and genetic drift.
.2. Established cell-lines
Long-established continuous cell-lines have the advantages of
eing easy to expand and relatively uniform, therefore showing
ess variability compared to primary cultures. Provided that the
ame experimental conditions are used, experiments with contin-
ous cell-lines can be repeated by different researchers all over the
orld adding to the reproducibility of experimental ﬁndings. The
ain criticisms towards them are again focused on selection bias,
henotypic and genetic drift (Wenger et al., 2004).
Currently, there are around 44 continuous medulloblastoma
ell-lines established over a period of four decades. Because of the
verwhelming diversity in characterisation methods used over the
ears, it can be very hard to see the full picture of the medulloblas-
oma cell-line landscape. Moreover, with the current molecular
lassiﬁcation of medulloblastoma, it is vital to ascertain the sub-
ype each cell-line belongs to in order to link preclinical data to
atients’ tumours. Two previous reviews have attempted to sys-
ematize the most common medulloblastoma cell-lines (Langdon
t al., 2006) and include information on their subgroup afﬁliation
Xu et al., 2015a). This review builds on their work by expanding
he number of classiﬁed cell-lines and including speciﬁc references
ith regards to the strength of evidence behind the classiﬁcationTable 1 and Fig. 1).
There is surprisingly little diversity in the genetic features for the
arge number of medulloblastoma cell-lines (Table 1 and Fig. 1). For
xample all Group 3 cell-lines harbour MYC  ampliﬁcation and 50%chnology 236 (2016) 10–25 13
of the classiﬁed SHH cell-lines (UW-228 and DAOY) have a muta-
tion in TP53. Indeed, even in the case of wild-type TP53 cell-lines,
TP53 function can also be supressed via MDM2 overexpression
(Ghassemifar and Mendrysa, 2012; Kunkele et al., 2012). Both MYC
ampliﬁcations and functional inactivation of TP53 are characteris-
tics of high-risk aggressive medulloblastoma. This may mean that
the more aggressive subtypes of medulloblastoma are generally
better suited to grow in vitro and even in cases where more aggres-
sive cells represent a minority population within the patient’s
tumour, the latter are selected and enriched through in vitro culture.
The early-passage MED6 cell line is most probably an example of
in-vitro selection. Whilst the parent tumour harboured a mutation
in codon 37 of CTNNB1, the MED6 cell-line exhibited a wild-type
sequence for the gene (Othman et al., 2014). These results suggest
that, while beta-catenin mutated cells were the dominating popu-
lation in the parent tumour, a subpopulation of cells with wild-type
beta-catenin were selected by culturing the cells in vitro.
The matched original tumour and metastasis cell-lines, D425
and D458 respectively, present an intriguing case because the cell-
line derived from the original tumour (D425) is TP53 mutated,
while the one derived from the metastasis (D458) is TP53 wild
type (Ghassemifar and Mendrysa, 2012; Lacroix et al., 2014). While
both possess the same R72P polymorphism, it appears that the TP53
mutation was not necessary for the propagation of the metastatic
cell-line. What makes this especially remarkable is the recent
report that MYC  and TP53 inactivation cooperate in medulloblas-
toma relapse in patients (Hill et al., 2015). The lack of information
regarding the P53 status of the original biopsies makes it hard to
establish whether the D425–D458 case is a real biological phe-
nomenon or an artefact of cell culture.
The long-established D283 cell-line presents another curiosity,
as it has been classiﬁed as either Group 4 (Snuderl et al., 2013)
or Group 3 (Sengupta et al., 2014; Weeraratne et al., 2012). There-
fore, the D283 cell-line, along with D721 and the newly established
USP-13-MED, have been placed in an intermediate group between
Groups 3 and 4. Both D283 and D721 show MYC  overexpression at
the mRNA and protein level and all three cell-lines exhibit OTX2
overexpression consistent with Group3/4 (Table 1). The uncertain-
ties of classifying these cell lines to either Group 3 or 4 are most
probably exacerbated by the similarities between the two groups
(Ramaswamy et al., 2016).
While SHH and Group 3 tumours are extensively represented
among cell-lines, there is a scarcity of in vitro models for Group
4 and especially WNT  tumours. Until recently there had been no
reports of WNT  cell-lines in culture. However Othman et al., 2014
reported a medulloblastoma cell-line (MED5R) with -catenin
mutation derived from a rare case of recurrent large-cell anaplastic
WNT  tumour. Similarly, there is only one pair of cell-lines (CHLA-
01-MED and CHLA-01R-MED), both derived from the same patient,
which have been classiﬁed as Group 4. This is intriguing as over 40%
of medulloblastoma tumours belong to this subgroup.
Finally, over half of the available cell-lines have not been sub-
typed or characterised to the standards of the molecular era of
medulloblastoma research. The usefulness of the past research with
these cells and any future experiments would greatly beneﬁt from
fuller characterisation and subtype classiﬁcation using methylation
or gene expression.
Table 2 shows a list of misidentiﬁed cell-lines and duplicate
cell-lines which are either clones or refer to another cell-line.
For example, TE-671 was the ﬁrst medulloblastoma cell-line to
be established (McAllister et al., 1977). Despite its initial wide-
spread use it was subsequently discovered to be a clone of the
rhabdomyosarcoma cell-line RD (Stratton et al., 1989). Similarly
the initially reported human VC312R cell-line was later reported
to be contaminated with mouse cells (Higgins et al., 2010; Parker
















Systematic assessment table of all available continuous medulloblastoma cell-lines arranged according to subtype and molecular characteristics. Evidence for subgroup afﬁliation is classiﬁed as Weak in cases of conﬂicting reports
and  inconclusive data pointing to more than one subgroup; Moderate- evidence based on a single marker with no transcriptional proﬁling; Strong-transcriptional proﬁling data available and cell-lines classiﬁed to subgroups
based  on array data compared to patient tumours. The ﬁrst references to mention each cell-line are referenced as superscript 1, references for speciﬁc claims are given as sequential superscript numbers. Abbreviations: M or
mut.-  mutated; wt-wild-type; WNT-wingless-related integrated site; CTNNB1- catenin-beta-1(beta-catenin); SHH-sonic hedgehog; NS-Nanostring; LCA-large-cell anaplastic; MYC-v-myc avian myelocytomatosis viral oncogene
homolog; MYCN-v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; OTX2-orthodenticle homeobox 2; PVT-1- plasmacytoma variant translocation 1 oncogene.
Cell-line Subtype P53 Evidence Strength Other features References
MED5R1 WNT1 CTNNB1 mutation1
nuclear -catenin IHC1
Moderate recurrent WNT  with
LCA histology1
1(Othman, 2014)
DAOY1 SHH2 M3 22 gene panel Nanostring (NS)2 Strong Tetraploid 1(Jacobsen et al., 1985)
2(Triscott et al., 2013);3(Saylors et al., 1991), (Lacroix et al., 2014)
UW2281
(3  cell lines same patient)
SHH2 M3 22 gene panel NS2 Strong 1(Keles et al., 1995);2(Triscott et al., 2013)
3(Kunkele et al., 2012; Lacroix et al., 2014)
UW4261 SHH2 – 22 gene panel NS2 Strong 1(Akiyama et al., 2001; Yokota et al., 2004);2(Triscott et al., 2013)
ONS-761 SHH2 Wt3 22 gene panel NS2 Strong 1(Yamada et al., 1989);2(Triscott et al., 2013)
3(Kunkele et al., 2012; Lacroix et al., 2014)
D3411 Group 32 Wt3 MYC ampliﬁcation1
Transcriptional proﬁle2
Strong 1(Friedman et al., 1988);2(Weeraratne et al., 2012)
3(Kunkele et al., 2012; Saylors et al., 1991)
D3841 Group 32 Wt3 MYC ampliﬁcation1
Transcriptional proﬁle2
Strong 1(Bigner et al., 1990; He et al., 1991);2(Weeraratne et al., 2012)
3(Ghassemifar and Mendrysa, 2012)
D4251
D4582







1(Bigner et al., 1990);
2(He et al., 1991)
3(Weeraratne et al., 2012)
4(Ghassemifar and Mendrysa, 2012; Lacroix et al., 2014)
D4871 Group 3 –  MYC ampliﬁcation2
OTX2 ampliﬁcation2
Moderate 1(Bigner et al., 1997; Strickland et al., 1995)
2(Boon et al., 2005; Siu et al., 2003)
D5561 Group 32 Wt3 MYC ampliﬁcation2 Moderate 1(Aldosari et al., 2002, 2000) mentioned by(Strickland et al., 1995)
2(Langdon et al., 2006);3(Petersen et al., 2014; Waye et al., 2015)
MED8A1 Group 32 Wt3 PVT1-MYC fusion2
MYC ampliﬁcation4
Strong 1T. Pietsch unpublished data; earliest publication(Lindsey, 2003)
2(Northcott et al., 2012a);3(Lacroix et al., 2014);4(Langdon et al., 2006)
MHH-MED-21 Group 3 Wt1 MYC ampliﬁcation1 Weak 1(Pietsch et al., 1994);
MB0021
MB0041
Group 31 – Gene expression panel1
MYC ampliﬁcation1
Strong 1(Bandopadhayay et al., 2014)
HD-MB031 Group 31 Wt1 MYC ampliﬁcation1
Transcriptional proﬁle1
Strong 1(Milde et al., 2012)
D2831 Group
42/33
Wt4 No MYC ampliﬁcation5
High-level gain6
GABRA5 expression3
Weak 1(Friedman et al., 1985); 2(Snuderl et al., 2013);
3(Sengupta et al., 2014);(Weeraratne et al., 2012)
4(Saylors et al., 1991)
5(Bigner et al., 1990); 6(Langdon et al., 2006; Siu et al., 2003)
D721MED1 Group 4/3 – 2 MYC copies2
High MYC  expression2
High OTX2 mRNA3,4
Low OTX2 protein4
1(Aldosari et al., 2002, 2000; Bigner et al., 1997)
2(Siu et al., 2003);3(Di et al., 2005);4(Boon et al., 2005)
























1(Xu et al., 2015b)









– CTNNB1 mut in tumour, but wt  in
cell-line1
Weak normal MYC1 1(Othman et al., 2014)
D581MED1 – – 2 MYC copies2






1(Strickland et al., 1995)
2(Siu et al., 2003)
3(Di et al., 2005)
4(Boon et al., 2005)
5(Aldosari et al., 2002)
D690MED1 – – – – – 1(Aldosari et al., 2002)
MHH-MED-11 – Wt1 2 MYC copies2 – 1(Pietsch et al., 1994);2(Siu et al., 2003)
MHH-MED-31 – Wt1 – – 1(Pietsch et al., 1994)
MHH-MED-41 – Wt1 2 MYC copies2 – 1(Pietsch et al., 1994);2(Siu et al., 2003)
RES3001 – – – – – 1(Sikkema et al., 2012)
Res  2621 – – – – 1(Kongkham et al., 2008)
Res  2561 – – – – 1(Bobola, 2005)
UW  4731 – – – – – 1(Bobola, 2005)
UW  4431 – – – – 1(Keles et al., 1995);
UW  4021 – – – – 1(Castro-Gamero et al., 2013)
CHLA-2591 – Wt1 High MYCN1 1(Xu et al., 2012)
MCD-11 – M1 1(Moore et al., 1996)
1580WÜ1 MMR  defﬁcient1 1(Hartmann et al., 2005; von Bueren et al., 2012)
DEV1 – – Used as a model of
differentiation2
1(Giraudon et al., 1993; Jennings et al., 1992)
2(Buzanska et al., 2001)
IPNN-81 – – 1(Rooprai et al., 1997)
Madsen1 – – 1(Ranger et al., 2010)
ONS-81  – – 1(Yamada et al., 1989)
BO-101 myomedulloblastoma (Giangaspero et al., 1991)
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Fig 1. Organisational chart of medulloblastoma cell-lines classiﬁed by molecular subtype. WNT  (blue); SHH-sonic hedgehog (red); Group 3 (yellow); Group3/4 (green-yellow);
Group 4 (green); Unclassiﬁed (grey). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. Popularity of cell-line use calculated by number of citations. A-raw citations, B
Frequency of medulloblastoma groups. Colours represent the various groups with WNT-b
classiﬁed as either Group 3 or 4 has been given a green-yellow colour. (For interpretation
version  of this article.)
Table 2
Misidentiﬁed and duplicate cell-lines.




clones of ONS-76 (Sun et al., 2013)
D3241 1synonym for DAOY (Cahan et al., 1994)
1TE-671 RD clone (Stratton et al., 1989)
VC312R 1mouse cell contamination (Higgins et al., 2010)-citations normalised to the number of years the cell-line has been available; C-
lue, SHH-red, Group 3 yellow and Group 4 green. The D283 cell-line which has been
 of the references to colour in this ﬁgure legend, the reader is referred to the web
reminders of the importance of cell-line authentication (Coecke
et al., 2005; Geraghty et al., 2014).
3.2.1. Linking the data to patients – proportion of patient
tumours covered
A systematic literature search for the number of citations for
each of the cell-lines from Table 1 revealed the most frequently-
used cell-lines in medulloblastoma research (Fig. 2), the raw data
and methodology are published in a linked Data in Brief arti-
cle (Ivanov et al., 2016). Unsurprisingly the oldest cell-line DAOY
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341, UW2283, D425 and D458 (Fig. 2A). The DAOY hegemony
n in vitro medulloblastoma research was not shaken even after
ccounting for the 31 years since the cell-line has been in cul-
ure (Fig. 2B). While the panel of SHH cell-lines is mentioned in
round half of medulloblastoma in vitro experiments, the largest
edulloblastoma subgroup- Group 4, represents around 1% of cita-
ions, even after dividing the citations by the number of years in
irculation for each cell line (Fig. 2B). Fig. 2B and C illustrate the
nding that more than 50% of patient tumours (when the number
f patients with Group 4 and WNT  tumours are combined) are not
epresented in preclinical medulloblastoma research. Furthermore,
irtually all of the Group 3 model cell-lines harbour MYC ampliﬁ-
ations (Fig. 1), a characteristic of only 17% of Group 3 tumours
Roussel and Robinson, 2013). Therefore in order to represent the
ull heterogeneity of patient tumours, there is an urgent need to
stablish and characterise more cell-line models of Group 4, WNT
nd Group 3 tumours (without MYC  ampliﬁcation) respectively.
.2.2. GEMM cell-lines
Genetically engineered mouse models (GEMMs) of medul-
oblastoma have been derived with the aim of recapitulating
edulloblastoma tumour development. Tumours in these models
evelop de novo in immunocompetent mice with natural tumour
nd stroma interactions. However, unlike medulloblastoma in
umans, which exhibits four types of histology and metastasizes
n 30% of patients, the majority of mouse models display classic
istology, and only three models develop metastases- Smo/Smo
Hatton et al., 2008), Sleeping beauty (Wu et al., 2012) and GTML
Swartling et al., 2010). The vast majority of GEMMs require a Trp53
egative background, whereas TP53 mutations are rare in medul-
oblastoma (10% of all patients), primarily seen in WNT  (16% within
roup) and SHH (21% within group) subtypes (Zhukova et al., 2013).
 recent paper (Pöschl et al., 2014) used agreement of gene expres-
ion analysis and k-means clustering to compare GEMMs  to patient
umours and demonstrated that most GEMMs  clustered in the SHH
ubgroup, one model with WNT  and one (GTML) with Group 3. The
rp53-negative background of the Myc-driven models placed them
omewhere between SHH and Group 3. Moreover, the SHH GEMMs
lustered closer to adult SHH medulloblastoma than to tumours in
nfants and children. In this respect, GEMMs  provide a useful plat-
orm to study in vivo phenomena, like increased blood-brain barrier
ermeability in WNT  tumours (Phoenix et al., 2016), but do not cur-
ently offer alternative sources of cells representative of Group 4,
P53 wt WNT  or Group 3 patient tumours.
Nevertheless, high-throughput screens with GEMM derived-
ells have been instrumental in projects aimed at repurposing exist-
ng chemotherapy agents for use in medulloblastoma (Morfouace
t al., 2014). Employing them in the screening phase identiﬁed two
romising FDA approved drugs, pemetrexed and gemcitabine, to
ake into in vivo studies. In subsequent experiments, the inclusion
f pemetrexed and gemcitabine, alongside standard cisplatin and
yclophosphamide chemotherapy, increased survival in patient-
erived xenograft models from 39 days for vehicle control animals
o 63 days for the combined 4-drug regimen. These studies have
esulted in a clinical trial evaluating the inclusion of gemcitabine
nd pemetrexed alongside standard chemotherapy for Group 3/4
atients (NCT01878617).
. In vitro models of the normal brain
.1. Reasons to include the normal brainWhile testing drugs on medulloblastoma cell-lines and primary
ultures provides clues about tumour drug sensitivity and potential
fﬁcacy of compounds, these experiments may  select for inher-chnology 236 (2016) 10–25 17
ently toxic compounds or exposure times. Therefore, normal tissue
controls need to be included in early-stage screens in order to
ascertain tumour selectivity and lack of normal tissue toxicity.
Apart from the plethora of side effects systemic chemotherapy
has on dividing tissues, such as the bone marrow and epithelial
tissues, CNS-targeted chemotherapy always carries the risk of neu-
rotoxicity. Cisplatin for example, notoriously damages the cochlea,
causing hearing loss in children with medulloblastoma (Lafay-
Cousin et al., 2013). Vincristine exhibits peripheral neurotoxicity
when given via the systemic route, and carries the risk of fatal
neurotoxicity if administered intrathecally (Alcaraz et al., 2002).
Neurotoxic side-effects are especially important for local drug
delivery strategies aimed at controlling leptomeningeal metastasis.
Intra-cerebrospinal ﬂuid administration of methotrexate is known
to cause leukoencephalopathy (Bhojwani et al., 2014) and lipo-
somal cytarabine requires concomitant dexamethasone to control
chemical arachnoiditis symptoms (Chamberlain, 2012). Therefore,
comparison of the toxicity of therapy towards normal brain tissue is
required from the earliest stage of drug development in addition to
the standard panel of in vitro safety assessments. The use of normal
tissue can help deﬁne the therapeutic window of chemotherapy
necessary to eliminate the tumour without causing major damage
to the brain.
4.2. Rodent neural stem cells
Mouse and rat foetal brain cultures have demonstrated the
ability to correctly identify neurotoxic compounds (Hayess et al.,
2013; Zurich et al., 2013). However, recent studies have shown
important interspecies differences in chemical and drug neuro-
toxicity towards rodents and humans (Baumann et al., 2015). The
long-standing concerns about the ability of animal cells to pre-
dict response in humans (Abbott et al., 1999; Leist and Hartung,
2013), have underpinned the use of human tissues for neurotoxicity
assessment.
4.3. Transformed human cells
The most easily accessible types of “normal” human cells are
the transformed human cell-lines. They have been derived from
healthy donors, are relatively stable, easy to expand and can be dif-
ferentiated to neurons and glia. The most commonly used examples
are induced pluripotent stem cells (iPS), the LUHMES cell-line and
the commercially available ReNCell lines (Hoffrogge et al., 2006;
Lotharius et al., 2002; Schwartz et al., 2015; Takahashi et al., 2007).
While these cell-lines can be used to inform research into neu-
rodevelopmental disorders and neurodegenerative diseases, their
application as normal brain surrogates in brain tumour research
is questionable. The transduction with SOX-2 (for iPS cells) or
MYC  (iPS, LUHMES, ReNCell) makes these cell types similar to SHH
and Group 3 medulloblastoma tumours respectively. The onco-
gene transformation and the tumorigenicity of the transformed
cell-lines, hinders their application as normal tissue surrogates and
necessitates the use of non-transformed normal tissues.
4.4. Human neural stem cells
Non-transformed human neural stem cells can be derived from
human umbilical cord blood stem cells (Buz˙an´ska et al., 2005),
human embryonic stem cells (Chambers et al., 2009) or foetal brain
tissue (Carpenter et al., 1999). One disadvantage of the former, less-
differentiated subtypes is that the embryonic stem cells need to
be cultured for a few weeks in long multistep protocols in order
to reach the neural stem cell state (Chambers et al., 2009; Zhang
et al., 2001). Moreover, there are substantial differences in gene
























































p8 D.P. Ivanov et al. / Journal of
tem cells and those derived from foetal brain (Shin et al., 2007).
oetal cultures display a more specialised, differentiated pheno-
ype, while the embryonic-derived neural stem cells represent an
arlier stage of development. Foetal brain tissue, on the other hand,
s very heterogeneous and the state of differentiation and the num-
er of achievable passages in culture depends on the gestational age
f the foetus at the time of isolation (Moors et al., 2009). Regardless
f the source, human neural stem cells need to be differentiated
owards neurons, glia and oligodendrocytes in order to form reli-
ble models of the human brain.
. Three-dimensional models
.1. Why  3D?
While the genetic makeup of medulloblastoma and neural cells
s essential for determining their suitability in representing patient
umours and the normal brain, in vitro culture conditions can inﬂu-
nce the phenotype, cell signalling and drug sensitivity to a large
xtent (Hickman et al., 2014). Simplistic monolayer cultures, where
 single layer of cells is attached to polystyrene, have unnaturally
ow cell densities, lack cell–cell or cell-extracellular matrix interac-
ions, and do not exhibit nutrient gradients or physiological levels
f oxygen. Therefore, it is not surprising that when conventional
onolayer cultures of medulloblastoma cell-lines are compared to
atient tumours, the cell-lines tend to cluster together and, not with
atient tumours of the same subtype (Lin et al., 2016).
.2. Multicellular 3D tumour spheroids
Multicellular tumour spheroids, ﬁrst popularised by Suther-
and et al., recapitulate the physiological characteristics of tumour
nd normal tissues in a superior way, compared to monolay-
rs. The majority of tumours and normal cells in vivo grow as
hree-dimensional tissues in contact with each other and the extra-
ellular matrix, displaying a gradient in oxygen levels (2–5%) and
utrients, depending on their proximity to blood vessels. In this
espect, cells cultured as spheroids can often synthesize their own
xtracellular matrix, mimicking natural cell–cell and cell-matrix
nteractions (Cukierman et al., 2001; Ekert et al., 2014). More-
ver, small avascular tumour micrometastases frequently display
 hypoxic core with quiescent cells which are more resistant to
adiation and chemotherapy (Carrera et al., 2010; Herrmann et al.,
008; Rodríguez-Enríquez et al., 2008). In this respect, multicellu-
ar tumour spheroids can be cultured to sizes beyond the diffusion
istance of oxygen (300–500 mm)  and exhibit similar gradients
nd resistance patterns (Doublier et al., 2012; Wartenberg et al.,
003). Culturing cells in three-dimensional models also inﬂuences
he stem cell compartment (Hussein et al., 2011) and drug sensitiv-
ty (Hussein et al., 2011; Smith et al., 2012). Finally, gene expression
roﬁles in spheroids have been reported to be closer to those of par-
nt tumours compared to monolayers (De Witt Hamer et al., 2008;
akai et al., 2010).
.3. Three-dimensional normal brain component
The normal cerebellum, adjacent to the tumour, is a complex
hree-dimensional structure composed of cerebellar nuclei, cere-
ellar granular neurons, Purkinje cells, stellate cells, basket cells,
strocytes, oligodendrocytes, microglia, ependymal cells covering
he fourth ventricle, cells of the choroid plexus, etc. Therefore realistic model of the normal human brain in the context of
edulloblastoma would need to be a 3D structure with a com-
lex network of differentiated neurons and glia along with some
rogenitor cells.chnology 236 (2016) 10–25
Human neurospheres fulﬁl most of the above conditions, albeit
presenting as a simple mix  of progenitors, glial and neuronal cells
(Campos, 2004; Moors et al., 2009). Importantly, they have the
potential to assess toxic effects on mixed cultures of neurons, astro-
cytes and oligodendrocytes taking into account the interactions
between the cell types and their toxicological implications. For
example glial cells can not only affect the differentiation of neurons
(Wang et al., 1994), but can also convert toxic compounds to active
metabolites (Ransom et al., 1987) or secrete apoptotic factors upon
drug treatment (Wang et al., 2011). Although neurospheres are
dominated by poorly-differentiated cells, these progenitors may
model important collateral damage targets in children’s brains.
For example, insults to the hippocampal structures known to host
progenitors, have been linked to neurocognitive deﬁcits in medul-
loblastoma patients (Riggs et al., 2014).
The neurons and glial cells in children’s brains are well-
differentiated, have established connections and are characterised
by an ongoing process of myelination, pruning and maturation. In
this respect, the latest neurosphere models (Ivanov et al., 2014)
are at a disadvantage in representing the child’s brain due to their
less-mature foetal phenotype. Making them more physiologically-
representative requires differentiation and maturation protocols.
Although some differentiation protocols have already been devel-
oped, they rely on reductionist monolayer cultures (Visan et al.,
2012) or chemotherapy agents to stop proliferation (Jagtap et al.,
2011; Smirnova et al., 2015). The cerebral organoid cultures devel-
oped by Lancaster et al., 2013 represent a major step in the
modelling of the human brain in vitro. However, in order to be useful
in chemical screens, future protocols need to be in high-throughput
format and take days before the start of drug treatment, not months.
Therefore, there is an urgent need to develop 3D in vitro models of
the human brain with non-transformed cells in a high-throughput
format and a short time to differentiation.
5.4. Spheroid co-cultures
Another vital aspect of modelling medulloblastoma is including
the interaction between normal and tumour tissue. The interplay
between tumour and host tissue has been repeatedly demonstrated
to affect chemosensitivity (Straussman et al., 2012), radiosen-
sitivity (Upreti et al., 2011), proliferation (Spink et al., 2006),
angiogenesis (Wartenberg, 2001), cell adhesion (Chambers et al.,
2011) and gene expression (Berg et al., 2014). Including a nor-
mal  tissue component has proven to be essential in the successful
development of lung cancer (Amann et al., 2014; Onion et al.,
2016), bladder cancer (Kilani et al., 2003, 2002) as well as glioblas-
toma models (Chintala et al., 1997; Go et al., 1997; Terzis et al.,
1997a, 1997b; Thorsen et al., 1997).The combined scientiﬁc evi-
dence suggests that models incorporating a tumour and normal
tissue component are more than the sum of their parts and exhibit
increased physiological relevance. In view of these considerations
the ultimate model of medulloblastoma is envisaged to be a co-
culture model of normal and tumour tissue where the viability of
each cell population can be determined separately (Ivanov et al.,
2015), provided that the right differentiation state can be achieved.
5.5. ECM
In the context of the brain, the extracellular matrix is a subject
that is often overlooked, despite constituting around 10–20% of the
volume of the brain (Rauch, 2007). The ECM is an important compo-
nent which affects cell signalling, drug distribution and metastasis
(Bellail et al., 2004). The brain ECM consist mainly of glycosamino-
glycans like chondroitin sulphate, hyaluronan, and complexes with
lectican, aggrecan and link proteins (Rauch, 2007). An important
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ith mainly collagen IV in the basement membrane layers of the
lood-brain barrier. The basement membrane is also the principal
ocation where laminin and ﬁbronectin are major ingredients of the
rain ECM. In this respect, in vitro matrices composed of collagen I
re physiologically-different from the brain parenchyma. Similarly
he laminin-rich Engelbreth-Holm-Swarm (EHS) mouse sarcoma
erived matrices (e.g. Matrigel) may  be more appropriate for blood-
rain barrier studies than modelling invasion throughout the brain.
herefore models incorporating these matrices (Deisboeck et al.,
001; Kumar et al., 2015) may  give a mechanistic clue of inva-
ion with regards to cell motility within gels, but extrapolation
f the ﬁndings to the clinical setting may  be limited. A potential
ay to overcome the above limitations is to use decellularised
rain ECM preparations which have been reported from porcine
DeQuach et al., 2011) and murine sources (De Waele et al., 2015;
hu et al., 2015). While these matrices have been derived from
rain tissues and contain a brain-speciﬁc mix  of glycosaminogly-
ans, interspecies differences in composition and pore size cannot
e ignored. Other alternatives are synthesizing tuneable hydrogels
nd tailoring them to match ECM components (Ananthanarayanan
t al., 2011; Karumbaiah et al., 2015). Adding to the complexity,
etastasis and invasion in the brain is also inﬂuenced by the inter-
ction of invading tumour cells with the normal neuronal and glial
ells and their spatial arrangement.
.6. Organotypic ex vivo models with cerebellar slices
In this respect, ex vivo cerebellar slices are the laboratory mod-
ls which offer the closest representation of the in vivo state of the
rain outside of the body (Lu et al., 2011). Organotypic brain slices
ave been derived from rodent pups (Stoppini et al., 1991) and adult
uman brain (Jung et al., 2002). They possess the in vivo-like archi-
ecture, mix  of differentiated cells in the right spatial organisation
nd the native extracellular matrix of the brain. These advantages
ave stimulated their use in experiments modelling tumour inva-
ion and metastasis in glioma (Aaberg-Jessen et al., 2013; Jung et al.,
002) as well as drug delivery in medulloblastoma (Meng et al.,
016, 2007). They have also been utilised to study the effects of
hemotherapy on the normal brain (Nørregaard et al., 2012). How-
ver the increased biological relevance of these models comes at
he price of low-throughput, demanding manual work to derive the
ultures, limited life-span and variability between different slice
reparations. Nevertheless organotypic cultures can serve as an
mportant bridge between cell-based in vitro cultures and in vivo
tudies- reducing and reﬁning the use of animals or taking advan-
age of leftover human brain tissue from epilepsy surgery (Eugène
t al., 2014).
. Data register/Cell-line database
This review has attempted to systematize all of the available
ell-lines for medulloblastoma research according to cell type
nd published molecular characteristics in the literature. Half
f medulloblastoma cell lines are poorly characterised and the
ata for the other half had to be extracted by piecing together
mall pieces of information from multiple papers. For example,
he genomic proﬁle of the second most commonly cited cell
ine, D283, has been uploaded many times to the NCBI’s Gene
xpression Omnibus (Edgar, 2002) (accession numbers GSE14437;
SE36133; GSM919357; GSM482336; GSE37412) by multiple
uthors (Barretina et al., 2012; Beroukhim et al., 2010; Dalwadi
nd Sunderland, 2008; Northcott et al., 2012a, 2009). Neverthe-
ess, it has been afﬁliated with Group 4 (Snuderl et al., 2013),
roup 3 (Sengupta et al., 2014; Weeraratne et al., 2012) and
ven WNT/SHH subtypes in some more controversial computer-chnology 236 (2016) 10–25 19
classiﬁcation approaches (Gendoo et al., 2015). The fragmented
state of cell-line characterisation can result in research with cells
which are not representative of patient tumours or using redundant
panels of Group 3 cell lines e.g. all with MYC-ampliﬁcation. This
work has identiﬁed 23 medulloblastoma cell lines which would
beneﬁt from further characterisation and subtyping.
A future platform for medulloblastoma model selection should
allow inclusion of the latest developments in the ﬁeld and amend-
ment of erroneous information from previous editions. Hence,
we are proposing a collaborative project via an online database
of medulloblastoma in vitro tools. The database would include
authentication data (short tandem repeats), molecular classiﬁca-
tion, and omics-type data as well as drug sensitivity information
for each cell line. It would enable individual researchers to upload
data from authenticated cell lines cultured as monolayers or more
physiologically-relevant in vitro and in vivo models and would facil-
itate comparisons with primary medulloblastoma tumours.
Another way of aiding researchers in choosing the right in vitro
tools would be establishing a central medulloblastoma cell bank
linked with the online database of all medulloblastoma cell lines.
The cell bank would serve as a reference source for each cell-
line allowing individual researchers to identify relevant cells to
answer their individual research questions and to access well-
characterised cells. The combination of cell bank and online data
repository would assist in rapid recognition of the gaps in preclin-
ical research in terms of representation of tumour types.
7. Conclusions and future directions
Since the establishment of the ﬁrst medulloblastoma cell-lines,
over four decades of in vitro medulloblastoma research has pro-
duced a wide variety of models to study medulloblastoma biology
and test potential therapies. Despite a great deal of biological char-
acterisation, one key piece of information is still missing. How good
are these models in predicting patient response? The predictive
potential of the current preclinical medulloblastoma models has
not been determined in a concerted systematic way.
The prevailing belief is that matching the molecular circuitry of
human tumours in the lab would yield better predictions. Never-
theless, the extent of complexity necessary for faithful predictions
of biological behaviour remains unknown. Researchers have inves-
tigated similarity in the genetic, epigenetic, RNA, protein and
metabolomics level without reaching consensus on what level of
agreement is good enough. For example, despite the vast amount
of in vitro and xenograft studies performed with the DAOY cell-
line, most clinicians would be reluctant to base treatment on these
data, even in cases of SHH tumours displaying the same molecular
features as DAOY (SHH, tetraploid and TP53 mutated).
In that respect, it is equally important to determine the added
value of culturing cells in 3D, using the right ECM and including a
normal brain component. Do interventions like these sufﬁciently
improve the predictive potential of models? In order to place
in vitro models in the clinical context, we would need to compare
their level of physiological similarity to the latest in vivo mod-
els of medulloblastoma and, more importantly, patient tumours.
Although agreement of gene expression analysis (AGDEX) and clus-
tering approaches have been used to compare mRNA proﬁles of
the latest GEMMs  to patient tumours, no cell-lines or primary cells
were included in that analysis (Pöschl et al., 2014). It would be
beneﬁcial to use the same methodology and compare the existing
cell-lines in 2D and 3D against mouse models and patient tumours.
This may  allow the level of similarity necessary for faithful predic-
tions of safety and efﬁcacy to be uncovered.
This review has mainly been concerned with in vitro models
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ble and overly simplistic. This is true when considering that most
onventional in vitro models do not account for drug distribu-
ion, metabolism or excretion. However, interspecies differences
re well-documented between human and rodents in blood-brain
arrier permeability (Shen et al., 2004), metabolism and excretion
Leist and Hartung, 2013; Rangarajan and Weinberg, 2003; Singh
nd Ferrara, 2012). The above limitations make the extrapolation
f all preclinical data to the clinic challenging. Nevertheless in silico
pproaches accounting for physiologically-based pharmacokinetic
odelling and machine-learning algorithms can help in improving
he predictive potential of preclinical studies (Schwartz et al., 2015;
oon et al., 2012).
In addition to model considerations, predictions of drug activ-
ty are related to drug exposure- concentrations achieved at the
arget over a period of time. While the majority of in vitro experi-
ents correlate drug concentration in media and maximum plasma
evels, this approach has a number of downsides. Drugs in in vitro
xperiments can bind to albumin and ECM components in cell cul-
ure media, they can be pumped out of the cells or distribute in
he wrong intracellular compartment (Groothuis et al., 2015). In
ivo, blood, CSF or brain parenchyma concentrations may  differ
rom intratumoral levels by several orders of magnitude (Muldoon
t al., 2007). Studies correlating in vitro cell-target levels with in vivo
ntratumoural target engagement over time are needed for reliable
redictions.
The full potential of in vitro models can be realized in prospec-
ive clinical trials, where tumour and normal tissue are collected
rom every patient, and short term in vitro cultures established
uring the course of treatment as in colorectal cancer, for example
van de Wetering et al., 2015). The intrinsic tumour and normal tis-
ue sensitivity to clinically-relevant therapeutic interventions can
e prospectively tested in vitro and compared to the outcomes of
linical treatment, allowing the construction of in vitro-in vivo cor-
elation mathematical models. This endeavour should also combine
enomic, transcriptomic and proteomic analysis to identify trends
etween molecular circuitry and drug sensitivity (Barretina et al.,
012; Garnett et al., 2012; Yang et al., 2013). The results can be
xtrapolated to other patients by computing similarity scores for
n vitro models, including cell lines, based on genomic, proteomic
r metabolomics data and predicting patient response through the
stablished machine-learning algorithms, validated in prospective
linical studies.
The way forward for useful preclinical models is to move away
rom the binary measures of sensitivity and resistance and correlate
arget drug exposures over time with clinical response. In addition,
linical response should not be reduced solely to tumour response
ut would ideally relate to survival and quality of life improve-
ent. The preclinical models of the future should always relate the
cquired data to patients and interpret them in the context of the
linical situation.
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